Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: LIMA1

Gene summary for LIMA1

Gene summary.

Gene information	Species	Human
	Gene symbol	LIMA1
	Gene ID	51474
	Gene name	LIM domain and actin binding 1
	Gene Alias	EPLIN
	Cytomap	12q13.12
	Gene Type	protein-coding
	GO ID	GO:0003008
	UniProtAcc	Q9UHB6

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
51474	LIMA1	P104T-E	Human	Esophagus	ESCC	2.51e-02	5.90e-01	0.0931
51474	LIMA1	P107T-E	Human	Esophagus	ESCC	1.83e-49	1.95e+00	0.171
51474	LIMA1	P126T-E	Human	Esophagus	ESCC	3.45e-02	1.20e+00	0.1125
51474	LIMA1	P127T-E	Human	Esophagus	ESCC	7.15e-09	6.61e-02	0.0826
51474	LIMA1	P128T-E	Human	Esophagus	ESCC	3.23e-14	8.24e-01	0.1241
51474	LIMA1	P130T-E	Human	Esophagus	ESCC	2.15e-28	9.48e-01	0.1676
51474	LIMA1	S43	Human	Liver	Cirrhotic	3.83e-04	-1.76e-01	-0.0187
51474	LIMA1	HCC1_Meng	Human	Liver	HCC	2.01e-54	3.63e-02	0.0246
51474	LIMA1	HCC2_Meng	Human	Liver	HCC	8.07e-65	7.75e-01	0.0107
51474	LIMA1	cirrhotic1	Human	Liver	Cirrhotic	1.24e-02	1.31e-01	0.0202
51474	LIMA1	cirrhotic2	Human	Liver	Cirrhotic	9.90e-05	1.00e-01	0.0201
51474	LIMA1	cirrhotic3	Human	Liver	Cirrhotic	3.25e-07	2.05e-01	0.0215
51474	LIMA1	HCC1	Human	Liver	HCC	3.53e-02	3.18e+00	0.5336
51474	LIMA1	Pt13.b	Human	Liver	HCC	1.75e-08	1.74e-01	0.0251
51474	LIMA1	S028	Human	Liver	HCC	7.91e-05	4.98e-01	0.2503
51474	LIMA1	S029	Human	Liver	HCC	1.46e-11	7.14e-01	0.2581
51474	LIMA1	RNA-P17T-P17T-2	Human	Lung	IAC	7.37e-04	5.40e-01	0.3371
51474	LIMA1	RNA-P17T-P17T-6	Human	Lung	IAC	4.69e-07	7.88e-01	0.3385
51474	LIMA1	RNA-P17T-P17T-8	Human	Lung	IAC	4.46e-06	6.16e-01	0.3329
51474	LIMA1	RNA-P25T1-P25T1-1	Human	Lung	AIS	3.88e-05	3.08e-01	-0.2116

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Colorectum (GSE201348)		FAP: Familial adenomatous polyposis
		CRC: Colorectal cancer
Colorectum (HTA11)		AD: Adenomas
		SER: Sessile serrated lesions
		MSI-H: Microsatellite-high colorectal cancer
		MSS: Microsatellite stable colorectal cancer
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
GC		CAG: Chronic atrophic gastritis
		CAG with IM: Chronic atrophic gastritis with intestinal metaplasia
		CSG: Chronic superficial gastritis
		GC: Gastric cancer
		SIM: Severe intestinal metaplasia
		WIM: Wild intestinal metaplasia
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Lung		AAH: Atypical adenomatous hyperplasia
		AIS: Adenocarcinoma in situ
		IAC: Invasive lung adenocarcinoma
		MIA: Minimally invasive adenocarcinoma
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Prostate		BPH: Benign Prostatic Hyperplasia
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:0007015	Colorectum	AD	actin filament organization	167/3918	442/18723	1.65e-16	7.94e-14	167
GO:0032535	Colorectum	AD	regulation of cellular component size	142/3918	383/18723	1.74e-13	3.41e-11	142
GO:1902903	Colorectum	AD	regulation of supramolecular fiber organization	139/3918	383/18723	2.01e-12	3.19e-10	139
GO:0032970	Colorectum	AD	regulation of actin filament-based process	142/3918	397/18723	4.05e-12	5.90e-10	142
GO:0110053	Colorectum	AD	regulation of actin filament organization	108/3918	278/18723	5.02e-12	6.98e-10	108
GO:0008154	Colorectum	AD	actin polymerization or depolymerization	90/3918	218/18723	6.14e-12	8.23e-10	90
GO:0008064	Colorectum	AD	regulation of actin polymerization or depolymerization	79/3918	188/18723	4.17e-11	4.74e-09	79
GO:0030832	Colorectum	AD	regulation of actin filament length	79/3918	189/18723	5.71e-11	6.27e-09	79
GO:0032956	Colorectum	AD	regulation of actin cytoskeleton organization	127/3918	358/18723	1.03e-10	1.04e-08	127
GO:0022411	Colorectum	AD	cellular component disassembly	147/3918	443/18723	8.53e-10	6.76e-08	147
GO:0032984	Colorectum	AD	protein-containing complex disassembly	81/3918	224/18723	9.41e-08	4.65e-06	81
GO:0010639	Colorectum	AD	negative regulation of organelle organization	114/3918	348/18723	1.41e-07	6.49e-06	114
GO:0061572	Colorectum	AD	actin filament bundle organization	60/3918	161/18723	1.33e-06	4.23e-05	60
GO:0051017	Colorectum	AD	actin filament bundle assembly	58/3918	157/18723	2.74e-06	7.89e-05	58
GO:1902904	Colorectum	AD	negative regulation of supramolecular fiber organization	60/3918	167/18723	5.23e-06	1.35e-04	60
GO:0051494	Colorectum	AD	negative regulation of cytoskeleton organization	58/3918	163/18723	1.04e-05	2.40e-04	58
GO:0030042	Colorectum	AD	actin filament depolymerization	27/3918	59/18723	1.65e-05	3.47e-04	27
GO:0006066	Colorectum	AD	alcohol metabolic process	106/3918	353/18723	3.02e-05	5.57e-04	106
GO:0030834	Colorectum	AD	regulation of actin filament depolymerization	24/3918	54/18723	8.58e-05	1.33e-03	24
GO:0030835	Colorectum	AD	negative regulation of actin filament depolymerization	20/3918	45/18723	3.28e-04	3.86e-03	20

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26

Enriched KEGG pathways.

Pathway ID

Tissue

Disease Stage

Description

Gene Ratio

Bg Ratio

pvalue

p.adjust

qvalue

Count

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

LIMA1

SNV

Missense_Mutation

c.578C>A

p.Pro193Gln

p.P193Q

Q9UHB6

protein_coding

deleterious(0)

probably_damaging(0.988)

TCGA-A2-A25A-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unspecific

Cytoxan

LIMA1

SNV

Missense_Mutation

c.772N>C

p.Glu258Gln

p.E258Q

Q9UHB6

protein_coding

deleterious(0.01)

possibly_damaging(0.71)

TCGA-A8-A095-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

5-fluorouracil

LIMA1

SNV

Missense_Mutation

c.2275N>A

p.Glu759Lys

p.E759K

Q9UHB6

protein_coding

deleterious(0.02)

possibly_damaging(0.476)

TCGA-AC-A23H-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

LIMA1

SNV

Missense_Mutation

rs763276725

c.889N>A

p.Glu297Lys

p.E297K

Q9UHB6

protein_coding

deleterious(0.04)

probably_damaging(0.996)

TCGA-AN-A046-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

LIMA1

SNV

Missense_Mutation

c.1943A>G

p.Asn648Ser

p.N648S

Q9UHB6

protein_coding

tolerated(1)

benign(0)

TCGA-AO-A128-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

doxorubicin

LIMA1

SNV

Missense_Mutation

c.178N>G

p.Leu60Val

p.L60V

Q9UHB6

protein_coding

tolerated(0.09)

benign(0.156)

TCGA-BH-A0HP-01

Breast

breast invasive carcinoma

Female

>=65

III/IV

Chemotherapy

doxorubicin

LIMA1

SNV

Missense_Mutation

novel

c.823N>A

p.Gln275Lys

p.Q275K

Q9UHB6

protein_coding

deleterious(0)

probably_damaging(0.99)

TCGA-S3-AA11-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Hormone Therapy

letrozole

LIMA1

SNV

Missense_Mutation

novel

c.1066N>T

p.Pro356Ser

p.P356S

Q9UHB6

protein_coding

tolerated(0.3)

benign(0.01)

TCGA-2W-A8YY-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

LIMA1

SNV

Missense_Mutation

c.150G>A

p.Met50Ile

p.M50I

Q9UHB6

protein_coding

tolerated(0.49)

benign(0.023)

TCGA-C5-A1BL-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Unknown

LIMA1

SNV

Missense_Mutation

rs781115938

c.1717N>A

p.Asp573Asn

p.D573N

Q9UHB6

protein_coding

deleterious(0.03)

probably_damaging(0.985)

TCGA-EK-A2RO-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Unknown

Page: 1 2 3 4 5 6 7 8

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1